COMPASS Pathways (CMPS) investor relations material

Executive summary

• Achieved primary endpoints in pivotal Phase 3 trials for COMP360 in treatment-resistant depression (TRD), demonstrating rapid and durable efficacy in over 1,000 participants, with a generally well-tolerated safety profile.

• FDA granted rolling NDA submission and review for COMP360 in TRD, with final NDA submission on track for Q4 2026 and launch readiness expected by year-end.

• Awarded a Commissioner's National Priority Voucher (CNPV), potentially accelerating FDA review to 1–2 months; White House executive order supports expedited DEA review for psychedelic treatments.

• Advanced development for PTSD, with late-stage trial setup, finalized Phase 2b/3 design, and strong engagement with the VA.

• No revenue generated; operations funded by equity, warrants, and debt financings.

Financial highlights

• Net income for Q1 2026 was $91.2 million, compared to a net loss of $17.9 million in Q1 2025, primarily due to a $130.9 million non-cash gain on warrant fair value adjustment.

• Operating expenses decreased to $42.9 million from $49.6 million year-over-year, driven by lower R&D and G&A costs.

• Cash and cash equivalents totaled $466 million as of March 31, 2026, up from $149.6 million at year-end 2025.

• Debt increased to $50.5 million from $31.6 million over the same period.

• Accumulated deficit stood at $731.4 million.

Outlook and guidance

• Cash position expected to fund operations and capital expenditures into 2028, excluding potential proceeds from outstanding PIPE warrants.

• 26-week data from COMP006 Part B expected in early Q3 2026, with final NDA submission on track for Q4 2026.

• Launch readiness initiatives underway, including commercial team buildout, payer engagement, and infrastructure scaling.

• Anticipates continued operating losses as R&D and commercialization activities increase, especially for COMP360 in TRD and PTSD.

• Additional funding may be required depending on regulatory, commercial, and development milestones.